Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26072
Title: Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities.
Austin Authors: Chinni, Vidyasagar ;El-Khoury, Hanna;Perera, Marlon ;Bellomo, Rinaldo ;Jones, Daryl A ;Bolton, Damien M ;Patel, Oneel
Affiliation: Intensive Care
Surgery (University of Melbourne)
Urology
Centre for Integrated Critical Care, The University of Melbourne, Parkville, Victoria, Australia
Issue Date: 19-Mar-2021
metadata.dc.date: 2021
Publication information: British Journal of Clinical Pharmacology 2021; online first: 19 March
Abstract: An outbreak of a novel coronavirus (COVID-19 or 2019-CoV) infection has posed significant threats to international health and the economy. Patients with COVID-19 are at risk of cytokine storm, acute respiratory distress syndrome (ARDS), reduced blood oxygenation, mechanical ventilation, and a high death rate. Although recent studies have shown remdesivir & dexamethasone as treatment options, there is an urgent need to find a treatment to inhibit virus replication and to control the progression of the disease. Essential biometal zinc has generated a lot of excitement as one of the promising candidates to reduce the severity of COVID-19 infection. Several published observations outlined in the review are the reasons why there is a global enthusiasm that zinc therapy could be a possible therapeutic option. However, the biggest challenge in realising the therapeutic value of zinc is lack of optimal treatment modalities such as dose, duration of zinc supplementation and the mode of delivery. In this review, we discuss the regulatory mechanism that hinges upon the bioavailability of zinc. Finally, we propose that intravenous zinc could circumvent the confounding factors affecting the bioavailability of zinc and allow zinc to achieve its therapeutic potential. If successful, due to advantages such as lack of toxicity, low cost and ease of availability, intravenous zinc could be rapidly implemented clinically.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26072
DOI: 10.1111/bcp.14826
ORCID: 0000-0002-5615-1815
PubMed URL: 33742473
Type: Journal Article
Subjects: Bioavailability
COVID-19
Immunity
Intravenous
Oral
SARS-COV-2
Zinc
Appears in Collections:Journal articles

Show full item record

Page view(s)

108
checked on May 17, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.